CO5611143A2 - Profarmacos de fosfatos de fluorooxindoles - Google Patents
Profarmacos de fosfatos de fluorooxindolesInfo
- Publication number
- CO5611143A2 CO5611143A2 CO04093294A CO04093294A CO5611143A2 CO 5611143 A2 CO5611143 A2 CO 5611143A2 CO 04093294 A CO04093294 A CO 04093294A CO 04093294 A CO04093294 A CO 04093294A CO 5611143 A2 CO5611143 A2 CO 5611143A2
- Authority
- CO
- Colombia
- Prior art keywords
- propharmaces
- fluorooxindol
- phosphate
- independently hydrogen
- enantiomer
- Prior art date
Links
- 229910019142 PO4 Inorganic materials 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004185 ester group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Un compuesto que tiene la fórmula caracterizado porque el enlace ondulado representa el racemato, el enantiómero (R) o el enantiómero (S), A es un enlace directo o (C=O); B es un enlace directo, oxígeno o nitrógeno; m es 0 ó 1; n es 1, 2 ó 3; R1 y R2 son cada uno independientemente hidrógeno o un grupo de éster hidrolizable, y cuando R1 es hidrógeno, R2 también puede ser -P(O)OR5OR6 o heteroarilo; R3 y R4 son cada uno independientemente hidrógeno o alquilo de C1-4 y R5 y R6 son cada uno independientemente hidrógeno o un grupo de éster hidrolizable;o una sal o solvato no tóxico y farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36601002P | 2002-03-20 | 2002-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5611143A2 true CO5611143A2 (es) | 2006-02-28 |
Family
ID=28454740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO04093294A CO5611143A2 (es) | 2002-03-20 | 2004-09-20 | Profarmacos de fosfatos de fluorooxindoles |
Country Status (21)
Country | Link |
---|---|
US (1) | US6930100B2 (es) |
EP (1) | EP1485085A4 (es) |
JP (1) | JP4359150B2 (es) |
KR (1) | KR100951499B1 (es) |
CN (1) | CN100384820C (es) |
BR (1) | BR0308737A (es) |
CA (1) | CA2479256A1 (es) |
CO (1) | CO5611143A2 (es) |
GE (1) | GEP20074230B (es) |
HR (1) | HRP20040853A2 (es) |
IL (2) | IL164022A0 (es) |
IS (1) | IS7456A (es) |
MX (1) | MXPA04008999A (es) |
NO (1) | NO20044442L (es) |
NZ (1) | NZ535365A (es) |
PL (1) | PL372413A1 (es) |
RS (1) | RS81904A (es) |
RU (1) | RU2312857C2 (es) |
UA (1) | UA77296C2 (es) |
WO (1) | WO2003080047A1 (es) |
ZA (1) | ZA200407337B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
US6916937B2 (en) * | 2003-02-03 | 2005-07-12 | Bristol-Myers Squibb Company | Carbohydrate prodrugs of fluorooxindoles |
US7169803B2 (en) * | 2004-03-15 | 2007-01-30 | Bristol-Myers Squibb Company | N-substituted prodrugs of fluorooxindoles |
US7253167B2 (en) | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
BRPI0606318B8 (pt) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição, e, uso de um composto |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
CN101282979B (zh) * | 2005-09-13 | 2011-09-21 | 卫材R&D管理有限公司 | 稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法 |
TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
TW200841879A (en) | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
WO2009100090A1 (en) * | 2008-02-05 | 2009-08-13 | Merck & Co., Inc. | Prodrugs of cgrp receptor antagonist |
US8188119B2 (en) * | 2008-10-24 | 2012-05-29 | Eisai R&D Management Co., Ltd | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same |
CA2766033C (en) * | 2009-06-25 | 2016-09-20 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
AU2010266018B2 (en) | 2009-06-25 | 2014-01-09 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
NZ604423A (en) | 2010-06-24 | 2015-01-30 | Alkermes Pharma Ireland Ltd | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
CN114380799A (zh) | 2015-07-06 | 2022-04-22 | 吉利德科学公司 | Cot调节剂及其使用方法 |
PE20211305A1 (es) | 2018-01-05 | 2021-07-20 | Cybrexa 1 Inc | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas |
JP7384812B2 (ja) | 2018-03-05 | 2023-11-21 | アルカームス ファーマ アイルランド リミテッド | アリピプラゾール投与戦略 |
WO2019173380A1 (en) * | 2018-03-05 | 2019-09-12 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
JP2022541747A (ja) | 2019-07-10 | 2022-09-27 | サイブレクサ 3,インコーポレイテッド | 治療薬としての微小管標的化剤のペプチドコンジュゲート |
US11634508B2 (en) | 2019-07-10 | 2023-04-25 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
JP7446475B2 (ja) | 2020-04-02 | 2024-03-08 | ギリアード サイエンシーズ, インコーポレイテッド | Cot阻害剤化合物を調製するためのプロセス |
EP3912625A1 (en) | 2020-05-20 | 2021-11-24 | Kaerus Bioscience Limited | Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5234947A (en) | 1991-11-07 | 1993-08-10 | New York University | Potassium channel activating compounds and methods of use thereof |
US5187173A (en) * | 1991-12-27 | 1993-02-16 | Sterling Winthrop Inc. | 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
US5565483A (en) * | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
CA2317008C (en) | 1997-12-31 | 2009-01-20 | The University Of Kansas | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
DE69912250T2 (de) * | 1998-01-29 | 2004-07-29 | Bristol-Myers Squibb Co., Wallingford | Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon |
-
2003
- 2003-03-20 WO PCT/US2003/008613 patent/WO2003080047A1/en active Application Filing
- 2003-03-20 BR BR0308737-9A patent/BR0308737A/pt not_active IP Right Cessation
- 2003-03-20 IL IL16402203A patent/IL164022A0/xx active IP Right Grant
- 2003-03-20 RS YUP-819/04A patent/RS81904A/sr unknown
- 2003-03-20 UA UA20041109513A patent/UA77296C2/uk unknown
- 2003-03-20 NZ NZ535365A patent/NZ535365A/en not_active IP Right Cessation
- 2003-03-20 EP EP03711659A patent/EP1485085A4/en not_active Withdrawn
- 2003-03-20 CA CA002479256A patent/CA2479256A1/en not_active Abandoned
- 2003-03-20 GE GEAP8458A patent/GEP20074230B/en unknown
- 2003-03-20 MX MXPA04008999A patent/MXPA04008999A/es active IP Right Grant
- 2003-03-20 PL PL03372413A patent/PL372413A1/xx not_active Application Discontinuation
- 2003-03-20 JP JP2003577875A patent/JP4359150B2/ja not_active Expired - Fee Related
- 2003-03-20 CN CNB038109778A patent/CN100384820C/zh not_active Expired - Fee Related
- 2003-03-20 RU RU2004131201/04A patent/RU2312857C2/ru not_active IP Right Cessation
- 2003-03-20 KR KR1020047014626A patent/KR100951499B1/ko not_active IP Right Cessation
- 2003-03-20 US US10/393,031 patent/US6930100B2/en not_active Expired - Lifetime
-
2004
- 2004-09-12 IL IL164022A patent/IL164022A/en not_active IP Right Cessation
- 2004-09-13 ZA ZA200407337A patent/ZA200407337B/en unknown
- 2004-09-17 HR HRP20040853 patent/HRP20040853A2/xx not_active Application Discontinuation
- 2004-09-17 IS IS7456A patent/IS7456A/is unknown
- 2004-09-20 CO CO04093294A patent/CO5611143A2/es not_active Application Discontinuation
- 2004-10-19 NO NO20044442A patent/NO20044442L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20044442L (no) | 2004-10-19 |
US6930100B2 (en) | 2005-08-16 |
JP2005526097A (ja) | 2005-09-02 |
IL164022A (en) | 2008-04-13 |
BR0308737A (pt) | 2005-01-11 |
US20030195169A1 (en) | 2003-10-16 |
EP1485085A4 (en) | 2007-03-14 |
PL372413A1 (en) | 2005-07-25 |
IL164022A0 (en) | 2005-12-18 |
MXPA04008999A (es) | 2004-12-07 |
CA2479256A1 (en) | 2003-10-02 |
WO2003080047A1 (en) | 2003-10-02 |
RU2004131201A (ru) | 2005-05-10 |
RS81904A (en) | 2007-02-05 |
GEP20074230B (en) | 2007-11-12 |
RU2312857C2 (ru) | 2007-12-20 |
HRP20040853A2 (en) | 2004-12-31 |
KR100951499B1 (ko) | 2010-04-07 |
AU2003215017A1 (en) | 2003-10-08 |
ZA200407337B (en) | 2006-02-22 |
CN100384820C (zh) | 2008-04-30 |
KR20040106293A (ko) | 2004-12-17 |
CN1652769A (zh) | 2005-08-10 |
UA77296C2 (en) | 2006-11-15 |
NZ535365A (en) | 2006-07-28 |
EP1485085A1 (en) | 2004-12-15 |
IS7456A (is) | 2004-09-17 |
JP4359150B2 (ja) | 2009-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5611143A2 (es) | Profarmacos de fosfatos de fluorooxindoles | |
TR200100432T2 (tr) | Hepatit C inhibitörü tri-peptidler | |
MY140680A (en) | Hepatitis c virus inhibitors | |
NO2013002I1 (no) | Aklidinium haogenid (Aklidinium bromid) | |
DE60106422D1 (de) | Dipeptidylpeptidase iv-inhibitoren | |
GEP20084505B (en) | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | |
RS50814B (sr) | Tartaratne soli 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)- heksadeka-2(11),3,5,7,9-pentaena | |
AP2002002637A0 (en) | Novel piperazine | |
GEP20043163B (en) | Inhibitors of Caspases, Pharmaceutical Composition on its Base and Method for its Production | |
GEP20084500B (en) | Heterocyclocarboxamide derivatives | |
HU9201329D0 (en) | The use of sulphonamides for medical purpose and process for the production of new sulphonamides | |
DK1663206T3 (da) | 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist | |
TW200732324A (en) | Novel compounds that are ERK inhibitors | |
GEP20074098B (en) | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
BG106013A (en) | New compounds and compositions as protease inhibitors | |
SE0102438D0 (sv) | New compounds | |
NO20034660D0 (no) | Spiropyrazolforbindelser | |
ATE399171T1 (de) | Camptothecinanaloge und deren zubereitungsmethoden | |
TR200201205T2 (tr) | N-ikame edilmiş karbamoiloksialkil-azolyum türevleri. | |
NO20051282L (no) | Antitumorale analoger av lamellariner. | |
DE60318826D1 (de) | Alkoxypyridinderivate | |
MXPA04009476A (es) | Compuestos de (tiazol-4,2-disustituidos-5-il)amina como inhibidores de la pde7. | |
MY135646A (en) | Indolyl derivatives | |
PT2112154E (pt) | Ésteres na posição 20 de camptotecinas | |
TW200505446A (en) | Inhibitor of cox |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |